Update on depression in neurologic illness: Stroke, epilepsy, and multiple sclerosis

Current Psychiatry Reports

Volumn 7, Issue 5, 2005, Pages 396-403

  Sobel, Richard M ^a   Lotkowski, Susan ^b   Mandel, Steven ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA INTERFERON; BETA1A INTERFERON; CARBAMAZEPINE; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DOPAMINE; FLUOXETINE; GLATIRAMER; INTERLEUKIN 1BETA; MIRTAZAPINE; MOCLOBEMIDE; NORADRENALIN; NORTRIPTYLINE; PHENOBARBITAL; PICROTOXIN; PILOCARPINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

AGE; BECK DEPRESSION INVENTORY; BEHAVIOR THERAPY; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHINESE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFIDENCE INTERVAL; COPING BEHAVIOR; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPEPSIA; EDUCATION; EMOTIONALITY; EPILEPSY; ETHNOLOGY; GABAERGIC SYSTEM; GERIATRIC PATIENT; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR DEPRESSION; MOOD DISORDER; MORTALITY; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; NORADRENERGIC SYSTEM; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEIZURE; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SUICIDE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 28044446350     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-005-0043-2     Document Type: Review

References (112)

1. Rickards H: Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005, 76(Suppl 1):i48-52.
2. Robinson RG: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003, 54:326-387.
3. Williams LS, Ghose SS, Swindle RW: Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry 2004, 161:1090-1095.
4. Tank WK, Chan SS, Chin HF, et al.: Poststroke depression in Chinese patients: frequency, psychosocial, clinical, and radiological determinants. J Geriatr Psychiatry Neurol 2005, 18:45-51.
5. Vataja R, Leppavuori A, Pohjasvaara T, et al.: Poststroke depression and lesion location revisited. J Neuropsychiatr Clin Neursci 2004, 16:156-162.
6. Robinson RG: Post-stroke mood disorder. Hosp Pract 1986, 83-89.
7. Cassidy E, O'Connor R, O'Keane V: Prevalence of post-stroke depression in an Irish sample and its relationship with disability and outcome following inpatient rehabilitation. Disabil Rehab 2004, 26:71-77.
8. Carson AJ, McHale S, Allen K, et al.: Depression after a stroke and lesion locator synthesis: a systematic review. Lancet 2000, 356:122-126.
9. Narushima K, Kosier JT, Robinson RG: A reappraisal of poststroke depression, intra- and inter hemispheric lesion location using meta-analysis. J Neuropsychiatry Clin Neurosci 2003, 5:423-430.
10. Desmond DW, Remien RH, Moroney JT, et al.: Ischemic stroke and depression. J Internat Meurophysiol Soc 2003, 9:429-439.
11. Rapoport MJ, McCullagh S, Shammi P, et al.: Cognitive impairment associated with major depression following mild and moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci 2005, 17:61-65.
12. Tang WK, Ungvari GS, Chiu HF, et al.: Detecting depression in Chinese stroke patients: a pilot study comparing four screening instruments. Int J Psychiatry Med 2004, 34:155-163.
13. Tang WK, Ungvari GS, Chiu HF, et al.: Screening post-stroke depression in Chinese older adults using the hospital anxiety and depression scale. Aging Mental Health 2004, 8:397-399,
14. Dieguez S, Staub F, Bruggimann L, et al.: Is poststroke depression a vascular depression? (Review). J Neurol Sci 2004, 226:53-58.
15. Kim JM, Stewart R, Shin IS, et al.: Vascular disease/risk and late-life depression in a Korean community population. Br J Psychiatry 2004, 185:102-107.
16. Neu P, Schlattmann P, Schilling A, et al.: Cerebrovascular reactivity in major depression: a pilot study. Psychosom Med 2004, 66:6-8.
17. Mast BT, MacNeill SE, Lichtenberg PA: Post-stroke and clinically-defined vascular depression in geriatric rehabilitation patients. Am J Geriatr Psychiatry 2004, 12:84-92.
18. Lipsey JY, Robinson RG, Pearlson GD, et al.: Nortriptyline treatment of post stroke depression: a double-blind study. Lancet 1984, 1:297-300.
19. Hackett ML, Anderson CS, House AO: Interventions for treating depression after stroke. [Review]. Cochrane Database Syst Rev 2004, 3:CD003437.
20. Rampello L, Chiechio S, Nicoletti G, et al.: Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology 2004, 173:73-78.
21. Andersen G, Vestergaard K, Lauritzen L: Effective treatment of post stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994, 25:1099-1104.
22. Niedermaier N, Bohrer E, Schulte K, et al.: Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 2004, 65:1619-1623.
23. Fruehald S, Gatterbauer E, Rehak P, et al.: Early fluoxetine treatment of post-stroke depression - a three-month double-blind placebo-controlled study with an open-abel long-term follow-up. J Neurol 2003, 250:347-351.
24. Jorge RE, Robinson RG, Arndt S, et al.: Mortality and poststroke depression, a placebo-controlled trial of antidepressants. Am J Psychiatry 2003, 160:1823-1829.
25. Erikkson M, Asplund K, Glader EL, et al.: Self-reported depression and use of antidepressants after stroke: a national survey. Stroke 2004, 35:936-941.
26. Wiart L, Petit H, Joseph PA, et al.: Fluoxetine in early post-stroke depression: the double-blind placebo-controlled study. Stroke 2000, 31:1829-1832.
27. Paolucci S, Antonucci G, Grasso MG, et al.: Poststroke oppression, antidepressant treatment and rehabilitation results. A case-controlled study. Cerebrovasc Dis 2001, 12:264-271.
28. Kimura M, Robinson RG, Kosier JT: Treatment of cognitive impairment after post of depression: a double-blind treatment trial. Stroke 2001, 32:1048-1049.
29. Cole MG, Elie LM, McCusker J: Feasibility and effectiveness of treatments for post-stroke depression and elderly inpatients: systematic review. J Geriatr Psychiatry Neurol 2001, 14:37-41.
30. Jorge RE, Robinson RG, Tateno A, et al.: Repetitive transcranial magnetic stimulation is treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004, 55:398-405.
31. Lincoln NB, Flannaghan T: Cognitive behavioral psychotherapy for depression following strokes: a randomized controlled trial. stroke 2003, 34:111-115.
32. Shoemaker N: Depression and stroke. Improving patient outcomes with a team approach. Caring 2001, 20:6-8.
33. Davis MC: Life review therapy as an intervention to manage depression and enhance life satisfaction in individuals with right hemisphere cerebral vascular accidents. Issues Mental Health Nurs 2004, 5:503-515.
34. Jones JE, Hermann BP, Barry H, et al.: Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005, 17:172-179.
35. Ettinger A, Reed M, Cramer J: Epilepsy Impact Project Group. Depression and comorbidity in community based patients with epilepsy or asthma Neurology 2004, 636:1008-1014.
36. Beghi E, Spagnoli P, Airoldi L, et al.: Emotional and affective disturbances in patients with epilepsy. Epilepsy Behav 2002, 3:225-261.
37. Schmitz B: Depression and mania in patients with epilepsy. Epilepsia 2005, 46(Suppl 4):45-49.
38. Piazzini A, Canevini MP, Maggiori G, Canger R: Depression and anxiety in patients with epilepsy. Epilepsy Behav 2001, 2:481-489.
39. Victoroff JI, Benson F, Grafton ST, et al.: Depression in complex partial seizures. Electroencephalograhy and cerebral metabolic correlates. Arch Neurol 1994, 51:155-163.
40. Quiske A, Helmstaedter C, Lux S, Elger CE: Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000, 39:121-125.
41. Helmstaedter C, Sonntag-Dillender M, Hoppe C, Elger CE: Depressed mood and memory impairment in temporal lobe epilepsy as a function of focus of lateralization and localization. Epilepsy Behav 2004, 5:696-701.
42. Mazza M, Orsucci F, De Riso S, et al.: Epilepsy and depression: risk factor for suicide? Clin Ter 2004, 155:425-427.
43. Caplan R, Siddarth P, Gurbani S, et al.: Depression and anxiety in pediatric epilepsy. Epilepsia 2005, 46:720-730.
44. Forsgren L, Nystrom L: An incident case referent study of epileptic seizures in adults. Epilepsy Res 1990, 6:66-81.
45. Herdorffer DC, Hauser WA, Annegers JF, Cascino G: Major depression is a risk factor for seizures in older adults. Ann Neurol 2000, 47:246-249.
46. Kanner AM, Balabanov A: Depression and epilepsy: how closely related are they? Neurology 2002, 58(8 Supp 5):27-39.
47. Jobe P: Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav 2003, 4(Supp 3):14-24.
48. Kanner AM: Depression in epilepsy: a frequently neglected multifaceted disorder. Epilepsy Behav 2003, 4(Suppl 4):11-19.
49. Paradiso S, Hermann BP, Blumer D, et al.: Impact of depressed mood on neuropsychological status in temporal lobe epilepsy. J Neurol Neurosurg Psychiatry 2001, 70:180-185.
50. Altshuler L, Rausch R, Delrahim S, et al.: Temporal lobe epilepsy, temporal lobectomy and major depression. J Neuropsychiatry Clin Neurosci 1999, 11:436-443.
51. Reuber M, Andersen B, Elger CE, Helmstaedter C: Depression and Anxiety before and after temporal lobe epilepsy. Seizure 2004, 13:129-135.
52. Cankurtaran ES, Ulug B, Saygi S, et al.: Psychiatric morbidity, quality of life and disability in mesial temporal lobe epilepsy patients before and after surgery. Epilepsy Behav 2005, 7:116-122. Abstract.
53. Wrench J, Wilson SJ, Bladin PF: Mood disturbance before and after seizure surgery: a comparison of temporal and extra temporal lobe resection. Epilepsia 2004, 45:534-543.
54. Quigg M, Broshek DK, Heidel-Schiltz S, et al.: Depression in intractable partial epilepsy varies by laterality of focus and surgery. Epilepsia 2003, 44:419-424.
55. Glosser G, Zwil AS, Glosser DS, et al.: Psychiatric aspects of TLE before and after anterior temporal lobectomy. Neurol Neurosurg Psychiatry 2000, 68:53-55.
56. Derry PA, Rose KJ, McLaclan RS: Moderators of the effect of preoperative emotional adjustment on post operative depression after surgery for temporal lobe epilepsy. Epilepsia 2000, 41:177-188.
57. Selai C, Bannister D, Trimble M: Antiepileptic drugs and the regulation of mood and quality of life (QOL): The evidence from epilepsy. Epilepsia 2005, 46(Supp 4):50.
58. Kalinin VV, Polyanskiy DA: Gender differences in risk factor of suicidal behavior in epilepsy. Epilepsy Behav 2005, 6:424-429.
59. Aldenkamp A-P, Arends J, Bootsma H-P, et al.: Randomized double blind parallel group study comparing cognitive effects of a low dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002, 43:19-26.
60. Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al.: Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav 2005, 6:413-416.
61. Savic I, Lindstrom P, Gulyas B, et al.: Limbic reduction of 5HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004, 52:1343-1351.
62. Theodore WH: Does serotonin play a role in epilepsy? Epilepsy Curr 2003, 3:173-177.
63. Pericic D, Lazic J, Svob Strac D: Anticonvulsant effects of acute and repeated fluoxetine treatment in unstressed and stressed mice. Brain Res 2005, 1033:90-95.
64. Clinkers R, Smolders I, Meurs A, et al.: Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem 2004, 89:834-843.
65. Hernandez EJ, Williams PA, Dudek FE: Effects of fluoxetine and TFMPP on spontenous seizures in Rats with pilocarpine induced epilepsy. Epilepsia 2002, 43:1337-1345.
66. Specchio LM, Iudice A, Specchio N, et al.: Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004, 27:133-136.
67. Preuter C, Norra C: Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005, 17:20-28.
68. Willer CJ, Ebers GC: Susceptibility to multiple sclerosis: interplay between genes and environment. Curr Opin Neurol 2000, 13:241-247.
69. Sotgiu S, Pugliatti M, Fois ML, et al.: Genes, environment and susceptibility to multiple sclerosis. Neurobiol Dis 2004, 17:131-143.
70. Minden SL, Orav J, Reich P: Depression in multiple sclerosis. Gen Hosp Psychiatry 1987, 9:426-434.
71. Sandovnick AD, Remick RA, Allen J, et al.: Depression and multiple sclerosis. Neurology 1996, 46:629-632.
72. Joffe RT, Lippert GP, Gray TA, et al.: Mood disorder and multiple sclerosis. Arch Neurol 1987, 44:376-378.
73. Schiffer RB, Caine ED, Bamford KA, Levy S: Depressive episodes in patients with multiple sclerosis. AM J Psychiatry 1983, 140:1498-1500.
74. Paten SB, Beck CA, Williams JV, et al.: Depression in multiple sclerosis: a population based perspective. Neurology 2003, 61:1524-1527.
75. Sadovnik AD, Eisen RN, Ebers GC, Paty DW: Cause of death in patients attending multiple sclerosis clinics. Neurology 1991, 41:1193-1196.
76. Feinstein A, Roy P, Lobaugh N, Feinstein K, et al.: Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004, 62:586-590.
77. Pujol J, Bello J, Deus J, Cardoner N, et al.: A. Beck Depression Inventory factors related to demyelinating lesions of the left arcuate fasciculus region. Psychiatry Res 2000, 99:151-159.
78. Berg D, Supprian T, Thomaae J, et al.: Lesion Pattern in patients with multiple sclerosis and dperssion. Mult Scler 2000, 6:156-162.
79. Benesova Y, Neidermayerova I, Mechl M, Havlikova P: The relation between brain MRI lesions and depressive symptoms in multiple sclerosis. Bratisl Lek Listy 2003, 104:174-176.
80. Zorzon M, De Masi R, Nasuelli D, et al.: Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 2001, 248:416-421.
81. Zorzon M, Zivadinoov R, Nasuelli D, et al.: Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 2002, 9:491-496.
82. Baskshi R, Zxzrnecki D, Shaikh ZA, Priore RL, et al.: Brain MRI lesions and atrophy are related to depression in multiple sclerosis 2003, 9:284-288.
83. Zhbad RK, Patten SB, Metz L: The association of depression with disease course in multiple sclerosis. Neurology 2005, 64:359-360.
84. Mikova O, Yakimova R, Bosmans E, et al.: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001, 11:203-208.
85. Kahl KG, Kruse N, Faller H, et al.: Expression of tumor necrosis factor alpha and interferon gamma mRNA in blood cell correlates with depression cores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002, 27:671-681.
86. Mohr DC, Gookin DE, Idlar J, et al.: Treatment of depression is associated with nonspecific and antigen specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001, 58:1081-1086.
87. Randolph JJ, Arnet PA: Depression and fatigue in relapsing-remitting MS: the role of symptomatic variability. Mult Scler 2005, 11:186-190.
88. Jannsens AC, van Doorn PA, de Boer JB, et al.: Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression and disease related distress. J Clin Epidemiol 2004, 57:180-186.
89. Jopson NM, Moss-Morris R: The role of illness severity and illness representations in adjusting to multiple sclerosis. J Psychosom Res 2003, 54:503-311.
90. Kneebone II, Dunmore EC, Evans E: Symptoms of depression in older adults with multiple sclerosis (MS): comparison with a matched sample of younger adults. Aging Ment Health 2003, 7:182-185.
91. Feinstein A: Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler 2000, 6:343-348.
92. Klapper MD: Letter to the editor [letter]. Neurology 1994, 44:188.
93. Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New Engl J Med 2000, 343:898-904.
94. Patten SB, Metz LM: Interferon B1a and depression in secondary progressive MS: Data from the SPECTRIMS trial. Neurology 2002, 59:744-746.
95. Patten SB, Metz LM: Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Multiple Scler 2001, 7:243-248.
96. Feinstein A, O'Connor P, Feinstein K: Multiple sclerosis, interferon beta 1-b and depression: A prospective investigation. J Neurol 2002, 249:815-820.
97. Mohr DC, Likosky W, Dwyer P, et al.: Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol 1999, 56:1263-1265.
98. Patten SB, Fridhandler S, Beck CA, Metz LM: Epressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003, 9:616-619.
99. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F, et al.: The relationship between depression and interferon beta therapy in patients with multiple sclerosis. Mult Scler 2005, 11:175-181.
100. Benedetti F, Campori E, Colombo C, Smeraldi E: Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci 2004, 16:364-366.
101. Schiffer RB, Wineman NM: Antidpressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990, 147:1493-1497.
102. Brank Y, Ur E, Achiron A: Mclobemide treatment in multiple sclerosis patients with comorbid depression: an open label safety trial. J Neuropsychiatry Clin Neurosci 1999, 11:271-273.
103. Scott TF, Nussbaum P, McConnell H, Brill P: Measurement of treatment response to sertraline in multiple sclerosis patients using the Carroll Scale. Neurol Res 1995, 7:421-422.
104. Feinstein A: The neuropsychiatry of multiple sclerosis. Can J Psychiatry 2004, 49:157-163.
105. Mohr DC, Boudewy AC, Goodkin DE, et al.: Comparative outcomes for individual cognitive behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of deprssion in multiple sclerosis. J Consulting Clin Psychol 2001, 69:942-949.
106. Mohr DC, Gookin DE: Treatment of Depression in multiple sclerosis. Clin Psychol Sci Pract 1999, 6:1-9.
107. Tesar N, Baumhackl U, Kopp M, Gunther V: Effects of psychological group therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica 2003, 107:394-399.
108. Mohr DC, Likosky W, Bertagnolli A, et al.: Telephone administered cognitive behavioral therapy for treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000, 68:356-361.
109. Rodgers D, Khoo K, MacEachen M, et al.: Cognitive therapy for multiple sclerosis: a preliminary study. Altern Ther Health Med 1996, 2:70-74.
110. Mohr DC, Hart SL, Goldberg A: Effects of treatment for depression on fatigue in multiple sclerosis. Pscyhosom Med 2003, 65:542-547.
111. Messmer UM, Mancuso ML, Battaglia MA, et al.: Peer support groups in multiple sclerosis: curret effectiveness and future directions. Mult Scler 2004, 10:80-84.
112. Mohr DC, Burke H, Beckner V, Merluzzi N: A preliminary report on a skills- based telephone- administered peer support program for patients with multiple sclerosis. Mult Scler 2005, 11:222-226.